Delving into the Latest Updates on RSV/hMPV mRNA Vaccine(Sanofi Pasteur) with Synapse

Overview

Basic Info

Drug Type

Prophylactic vaccine, mRNA vaccine

Synonyms

RSV/hMPV vaccine(Sanofi Pasteur), Respiratory Syncytial Virus/Human Metapneumovirus Vaccine(Sanofi Pasteur)

Target-

Mechanism

Immunostimulants

Therapeutic Areas

Infectious Diseases

Active Indication

Human Metapneumovirus InfectionRespiratory Syncytial Virus InfectionsParainfluenzae virus infection+ [1]

Inactive Indication-

Originator Organization

Sanofi Pasteur

Active Organization

Sanofi Pasteur

Inactive Organization-

Drug Highest PhasePhase 1/2

First Approval Date-

Regulation-

Login to view timeline

A Phase 1, Dose-Escalation, Randomized, Active-Controlled, Modified Double-Blind, Parallel-Group, Multi-Arm Study to Investigate the Safety and Immunogenicity of a Combined Respiratory Syncytial Virus/Human Metapneumovirus/Parainfluenza Virus Type 3 Vaccine Candidate in Adult Participants Aged 60 Years and Older

The purpose of this phase 1 study is to evaluate whether the vaccine is safe and can help the body to develop germ fighting agents called "antibodies" (immunogenicity) against the respiratory syncytial virus (RSV), human metapneumovirus (hMPV), and parainfluenza virus type 3 (PIV3). The study will use different doses of PIV3 only and different combinations of RSV/hMPV/PIV3 or RSV/hMPV or only RSV vaccine in adults aged 60 years and older.

Start Date17 Sep 2024

Sponsor / Collaborator

Sanofi Pasteur

NCT06237296 / Active, not recruitingPhase 1

A Phase I, Dose-escalation, Parallel-group, Randomized, Multi-center Study to Assess Safety and Immunogenicity of an RSV/hMPV mRNA Vaccine Candidate in Healthy Participants Aged 18 to 49 Years and 60 Years and Older.

The purpose of this study is to evaluate the safety and immunogenicity an investigational messenger ribonucleic acid (mRN)A vaccine for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) and/or human metapneumovirus (hMPV) in older adults. A single intramuscular (IM) injection of 3 to 4 different doses of the RSV/hMPV mRNA vaccine candidate formulated with 2 different lipid nanoparticles (LNP) will be administered to healthy participants aged 18 to 49 years and 60 years and older.
Treatment:
* RSV/hMPV mRNA / LNP 1 at 3-4 different doses or,
* RSV/hMPV mRNA / LNP 2 at 3-4 difference doses or,
* RSV mRNA / LNP 1 at 1 dose or,
* hMPV mRNA / LNP 1 at 1 dose

Start Date23 Jan 2024

Sponsor / Collaborator

Sanofi Pasteur

100 Clinical Results associated with RSV/hMPV mRNA Vaccine(Sanofi Pasteur)

Login to view more data

100 Translational Medicine associated with RSV/hMPV mRNA Vaccine(Sanofi Pasteur)

Login to view more data

100 Patents (Medical) associated with RSV/hMPV mRNA Vaccine(Sanofi Pasteur)

Login to view more data

9

Literatures (Medical) associated with RSV/hMPV mRNA Vaccine(Sanofi Pasteur)

01 Sep 2022·Immunity

Potently neutralizing and protective anti-human metapneumovirus antibodies target diverse sites on the fusion glycoprotein

Article

Author: McLellan, Jason S ; Rush, Scott A ; Walker, Laura M ; Wec, Anna Z ; Delgado, Teresa ; Rappazzo, C Garrett ; Sakharkar, Mrunal ; Geoghegan, James C ; Más, Vicente ; Hsieh, Ching-Lin ; Esterman, Emma S

Human metapneumovirus (hMPV) is a leading cause of acute lower respiratory tract infections in high-risk populations, yet there are no vaccines or anti-viral therapies approved for the prevention or treatment of hMPV-associated disease. Here, we used a high-throughput single-cell technology to interrogate memory B cell responses to the hMPV fusion (F) glycoprotein in young adult and elderly donors. Across all donors, the neutralizing antibody response was primarily directed to epitopes expressed on both pre- and post-fusion F conformations. However, we identified rare, highly potent broadly neutralizing antibodies that recognize pre-fusion-specific epitopes and structurally characterized an antibody that targets a site of vulnerability at the pre-fusion F trimer apex. Additionally, monotherapy with neutralizing antibodies targeting three distinct antigenic sites provided robust protection against lower respiratory tract infection in a small animal model. This study provides promising monoclonal antibody candidates for passive immunoprophylaxis and informs the rational design of hMPV vaccine immunogens.

01 Dec 2020·Journal of Medical VirologyQ4 · MEDICINE

The role of M2‐2 PDZ‐binding motifs in pulmonary innate immune responses to human metapneumovirus

Q4 · MEDICINE

Article

Author: Bao, Xiaoyong ; Chen, Yu ; Choi, Eun‐Jin ; Yan, Weiyu ; Wu, Wenzhe ; Choudhury, Atanu ; Li, Liqing

AbstractHuman metapneumovirus (HMPV) is a leading cause of lower respiratory tract infection (LRTI) in pediatric and geriatric populations. We recently found that two PDZ‐binding motifs of the M2‐2 protein, 29‐DEMI‐32 and 39‐KEALSDGI‐46, play a significant role in mediating HMPV immune evasion in airway epithelial cells (AECs). However, their role in the overall pulmonary responses to HMPV infection has not been investigated. In this study, we found that two recombinant HMPVs (rHMPV) lacking the individual M2‐2 PDZ‐binding motif are attenuated in mouse lungs. Mice infected with mutants produce more cytokines/chemokines in bronchoalveolar lavage (BAL) fluid compared to mice infected with wild‐type rHMPV. In addition, both mutants are able to enhance the pulmonary recruitment of dendritic cells (DCs) and T cells and induce effective protections against the HMPV challenge. The DC maturation is also significantly improved by the motif mutation. Taken together, our data provide proof‐of‐principle for two live‐attenuated M2‐2 mutants to be promising HMPV vaccine candidates that are effective in inducing higher pulmonary innate immunity and generating protection against HMPV infection.

01 Oct 2019·Journal of VirologyQ2 · MEDICINE

A Potent Neutralizing Site III-Specific Human Antibody Neutralizes Human Metapneumovirus In Vivo

Q2 · MEDICINE

Article

Author: Murray, Jackelyn ; Huang, Jiachen ; Diaz, Darren ; Pena-Briseno, Alma ; Mousa, Jarrod J. ; Bar-Peled, Yael ; Tripp, Ralph A.

Recent progress in understanding the human immune response to respiratory syncytial virus has paved the way for new vaccine antigens and therapeutics to prevent and treat disease. Progress toward understanding the immune response to human metapneumovirus (hMPV) has lagged behind, although hMPV is a leading cause of lower respiratory tract infection in children. In this report, we advanced the field by isolating a panel of human mAbs to the hMPV F protein. One potent neutralizing mAb, MPV364, targets antigenic site III on the hMPV F protein and incorporates two protomers into its epitope yet is unique from previously discovered site III mAbs, as it does not cross-react with the RSV F protein. We further examined MPV364 in vivo and found that it limits viral replication in BALB/c mice. Altogether, these data provide new mAb candidates for therapeutic development and provide insights into hMPV vaccine development.

100 Deals associated with RSV/hMPV mRNA Vaccine(Sanofi Pasteur)

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Human Metapneumovirus Infection	Phase 2	US	Sanofi Pasteur	01 Nov 2023
Human Metapneumovirus Infection	Phase 2	PR	Sanofi Pasteur	01 Nov 2023
Respiratory Syncytial Virus Infections	Phase 2	PR	Sanofi Pasteur	01 Nov 2023
Respiratory Syncytial Virus Infections	Phase 2	US	Sanofi Pasteur	01 Nov 2023
Parainfluenzae virus infection	Phase 1	AU	Sanofi Pasteur	17 Sep 2024
Metapneumovirus infection	Phase 1	AU	Sanofi Pasteur	23 Jan 2024
Metapneumovirus infection	Phase 1	US	Sanofi Pasteur	23 Jan 2024